Acetylcholinesterase inhibitors in Alzheimer's disease

British Journal of Clinical Pharmacology

Volumn 48, Issue 4, 1999, Pages 471-480

  McGleenon, B M ^a,b   Dynan, K B ^a   Passmore, A P ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b Whitla Medical Building ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; METRIFONATE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG COST; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; REVIEW; VOMITING;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; DRUG EVALUATION; HUMANS;

EID: 0032847780     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00026.x     Document Type: Review

References (56)

1. 1 Khann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
2. 2 Katzman R, Saitoh T. Advances in Alzheimer's Disease. FASEB J 1991; 5: 278-286.
3. 3 Becker RE, Becker RE, Giacobini E, editors. Cholinergic Basis of Alzheimer Therapy. Boston: Berkhauser 1991. Therapy of the cognitive deficit in Alzheimer's disease; the cholinergic system. p. 1-22.
4. 4 Cutler NR, Sramek JJ, Veroff AE. Alzheimer's Disease. Chichester: John Wiley and Sons, 1994.
5. 5 Becker RE, Giacobini E. Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type; clinical pharmacological and therapeutic aspects. Drug Dev Res 1988; 12: 163-195.
6. 6 Avery EE, Baker LD, Asthana S. Potential role of muscarinic agonists in Alzheimer's Disease. Drugs Aging 1997; 11: 450-459.
7. 7 Jorm AF. Effects of cholinergic enhancement therapies on memory function in Alzheimer's disease: a meta-analysis of the literature. Aust N Z J Psychiatry 1986; 20: 237-240.
8. 8 Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's Disease. Am J Psychiatry 1984; 141: 1356-1364.
9. 9 Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E. A longitudinal study of Alzheimer's disease; measurement rate and predictors of cognitive deterioration. Am J Psychiatry 1994; 151: 390-396.
10. 10 Kramer-Ginsberg E, Mohs RC, Aryan M, et al. Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report. Psychopharmacol Bull 1988; 24: 458-462.
11. 11 Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, National Institute of Mental Health 76 388, 1976, Clinical Global Impressions.
12. 12 Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Fiegel G. Mild senile dementia of the Alzheimer type. Evaluation of intervention. Ann Neurol 1992; 31: 242-249.
13. 13 Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
14. 14 Lawton MP, Brodie EM. Assessment of older people: self maintaining and instrumental activities of daily living. Gerontologist 1969; 11: 545-554.
15. 15 Schwartz GE. Development and evaluation of the Geriatric Evaluation by Relative's Rating Instrument (GERRI). Psychol Reports 1983; 53: 479-488.
16. 16 DeJong R, Osterlund OW, Roy GW. Measurement of quality of life changes in patients with Alzheimer's Disease. Clin Ther 1989; 11: 545-554.
17. 17 Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-1139.
18. 18 Cummings JL, Mega M, Gray K, Rosenberg Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory; comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2314.
19. 19 Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen, Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48 Suppl: 9-15.
20. 20 Peripheral and Central Nervous System Drugs Advisory Committee J. Rockville MD: Dept of Health and Human Services, Public Health Service, Food and Drug Administration 1989, 227.
21. 21 The European Agency for the Evaluation of Medical Products Committee for Propriety Medicinal Products (CPMP) S1. Notes for guidance on medical products in the treatment of AD. EMEA 1997.
22. 22 Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioural, and global function in patients with Alzheimer's disease. Neurology 1998; 50: 1222-1230.
23. 23 Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br Med J 1999; 318: 633-640.
24. 24 Selen A, Balogh L, Siedlik P. Pharmacokinetics of tacrine in healthy subjects. Pharm Res 1988; 5: S218.
25. 25 McNally W, Roth M, Young R. Quantitative whole-body autoradiographic determination of tacrine tissue distribution in rats following intravenous or oral dose. Pharm Res 1989; 6: 924-930.
26. 26 Neilsen JA, Mena EE, Williams IH. Correlation of brain levels of 9-amino-1,2,3,4 tetrahydroaminoacridine (THA) with neurochemical and behavioral changes. Eur J Pharmacol 1989; 173: 53-64.
27. 27 Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[5, 6-dimethoxy-1-indanon-2-yl] methylpiperidine hydrochloride (E2020) and related compounds. Bioorg Med Chem Lett 1992; 2: 871-876.
28. 28 Rogers SL, Yamanishi Y, Yamatsu K. Becker R, Giacobini E, eds. Cholinergic Basis for Alzheimer Therapy. 3rd ed. Boston: Birkhäuser 1991 E2020 - The pharmacology of a piperidine cholinesterase inhibitor. p. 314-320.
29. 29 Bryson HM, Benfield P. Donepezil. Drugs & Aging 1997; 10: 234-249.
30. 30 Rogers SL, Tiseo PJ, Friedhoff LT. Pharmacokinetics of donepezil HCL (E2020) are unchanged in patients with impaired renal function. Clin Pharmacol Ther 1997; 61: 217-220.
31. 31 Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with Exelon (ENA 713) in Alzheimer's disease: an overview. J Drug Dev Clin Pract 1996; 8: 109-116.
32. 32 Anand R, Gharabawi G. Clinical development of Exelon (ENA-713): the ADENA program. J Drug Dev Clin Pract 1996; 8: 117-122.
33. 33 Enz A, Amstutz R, Boddeke H. Brain selective inhibition of acetylcholinesterase: a novel approach to therpy for Alzheimer's disease. Prog Brain Res 1993; 98: 431-438.
34. 34 Reiner RE, Kraulhacker B, Simeon V, Skinjaric Spoiler M. Mechanisms of inhibition in vitro of mammalian acetylcholinesterase and cholinesterase in solutions of 0,0-dimethyl 2,2,2-trichloro-1-hydroxyethyl phosphate (trichorphon). Biochem Pharmacol 1975; 24: 717-722.
35. 35 Nordgren I, Bengtsson E, Holmstedt B, Pettersson BM. Levels of metrifonate and dichlorvos in plasma and erythrocytes during treatment of schistosomiasis with Bilarcil. Acta Pharmacol Toxicol 1981; 49 Suppl 5: 79-86.
36. 36 Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer's disease. Lancet 1991; 337: 989-992.
37. 37 Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994; 271: 985-991.
38. 38 Farlow M, Gracon SI, Hershey LA, et al. for the The Tacrine Study Group. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268: 2523-2529.
39. 39 Knopman D, Schneider L, Davis K, et al. for the Tacrine Study Group. Long term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996; 47: 166-177.
40. 40 Knopman D, Schneider L, Davis K, Gracon S, Smith F. Long-term tacrine treatment effects. Neurology 1998; 50: 567-8.
41. 41 Qizilbash N, Whithead A, Higgins J, Wilcock G, Schneider L, Farlow M. Cholinesterase inhibition for Alzheimer disease. A meta-analysis of the tacrine trials. JAMA 1998; 280: 1777-1782.
42. 42 Rogen SL, Friedhoff LT, The Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease; results of a US multicentre randomised double blind placebo-controlled trial. Dementia 1996; 7: 293-303.
43. 43 Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, Donepezil Study Group. A 24 week double blind placebo controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-145.
44. 44 Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021-1031.
45. 45 Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8: 67-75.
46. 46 Corey-Bloom J, Anand R, Veach J, The ENA 713 B352 Study Croup. A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65.
47. 47 Becker RE, Colliver J, Elble R, et al. Effects of metrifonate, a long acting cholinesterase inhibitor, in Alzheimer's disease; report of an open trial. Drug Dev Res 1990; 19: 425-434.
48. 48 Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B, The Metrifonate Study Group. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998; 50: 1214-1221.
49. 49 Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-998.
50. 50 Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994; 84: 1261-1264.
51. 51 Bosanquet N, May J, Johnson N. Alzheimer's Disease in the United Kingdom. Health Policy Review 1998 no. 12.
52. 52 Lubeck DP, Mazonson PD, Bowe T. Potential effect of tacrine on expenditures for Alzheimer's Disease. Med Interface 1994; (October): 130-138.
53. 53 Ernst RL, Hay JW, Fenn C, Tinklenberg J, Yesavage JA. Cognitive function and the costs of Alzheimer disease. An exploratory study. Arch Neurol 1997; 54: 687-693.
54. 54 Friedhoff LT, Rogers SL. Donepezil lengthens time to loss of activities of daily living inpatients with mild to moderate Alzheimer's Disease - results of a preliminary evaluation. Neurology 1997; 48: 2-26.
55. 55 Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer's disease: A Markov-cycle evaluation of five years' therapy using donepezil. Int J Geriat Psychiatry 1998; 13: 445-453.
56. 56 Standing Medical Advisory Committee. The use of Donepezil for Alzheimer's Disease. Department of Health, May 1998.